D. Legrand

Independent evaluation of tolerance of therapeutic plasma inactivated by amotosalen‐HCl–UVA (Intercept™) over a 5‐year period of extensive delivery

O. Garraud, F. Cognasse, P. Chavarin, 2015, Vox sanguinis.

In fl ammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study

J. Casanova, P. Gallian, S. Susen, 2022 .

Measures to prevent transfusion‐related acute lung injury (TRALI)

P. J. Norris, P. Tomasulo, S. Kleinman, 2012, Vox sanguinis.

Prophylactic platelet transfusions

P. Rebulla, V. Deneys, G. Escolar, 2012, Vox sanguinis.

Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study

J. Casanova, P. Gallian, P. Morel, 2022, eBioMedicine.

Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology

P. Morel, P. Tiberghien, F. Cognasse, 2022, Frontiers in Immunology.

Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study

P. Gallian, F. Pirenne, F. Cognasse, 2023, EBioMedicine.